# IMMP earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/IMMP) · [Earnings tab](https://www.lopjlb.com/stock/IMMP?tab=earnings) Updated: 2026-09-02T07:36:53 Quarters analyzed: 2 ## Cross-quarter narrative Across the two calls the company’s focus shifted from early‑stage financing and Phase‑2 trial set‑up (Q1) toward execution of a new CANVAS trial and related operational matters (Q4). In Q1 management highlighted cash‑runway concerns, a Share Purchase Plan, a Saxony grant and manufacturing scale‑up, while noting on‑track Phase‑2 milestones and a range of financing and clinical development fears. By Q4 those financing themes receded, replaced by recruitment‑related risks for the CANVAS trial, immune‑monitoring data releases, foreign‑exchange hedging and a push toward US investor outreach. Manufacturing and competitive risks were no longer emphasized, suggesting reduced immediate concern. New risks emerged around patient enrollment variability, currency exposure and media strategy, while earlier fears about cash balance and grant‑funded Phase‑2 work persisted implicitly as still‑open milestones. Overall the narrative reflects a transition from capital‑raising and set‑up activities to trial execution and market‑facing initiatives, with a mixed pattern of risk evolution: some earlier fears fade, while new operational and market‑related uncertainties arise. ## Latest CallCard · Q4 Prima Biomed discusses CANVAS trial recruitment strategy, ICS immune monitoring data, FX hedging, and US investor outreach in Q4 2013 call. **Guidance:** vague — No explicit financial guidance discussed in call. **Tone:** mgmt 0 · Q&A pressure 0.4 · divergence 0 No prepared remarks provided in transcript; management responses in Q&A appear measured and factual. ### Demand visibility Clinical trial patient recruitment visibility discussed; investor interest noted. Management describes CANVAS trial targeting up to 80 clinical centers, with recruitment rates varying from 0.5 to 1 patient per center per month depending on referral base. Increased US trading volume attributed to investor outreach and biotech sector interest. ### Milestones - **CANVAS trial** [on_track]: Targeting up to 80 clinical centers, up to 50 manufacturing centers; recruitment rates 0.5-1 patient per center per month. - **ICS immune monitoring data release** [on_track]: Analyzing longitudinal immune profiles across all 63 patients from baseline through dosing. - **US investor outreach** [delivered]: Increased US trading volume attributed to investor meetings and ASCO conference exposure. - **Foreign exchange hedging** [on_track]: Holding significant EUR and USD positions; hedging contracts based on projected operations. - **Australian media presence** [at_risk]: Focus shifted to US; cautious about over-communication; considering high-profile ovarian cancer advocacy but conservative approach. ### Fears / risks - **Clinical trial recruitment**: Recruitment rates vary significantly by center; patient enrollment challenging post-diagnosis. - **Foreign exchange**: Exposure to AUD weakening; hedging based on projected operations but significant EUR/USD holdings provide buffer. - **Media and communication**: Balancing US vs Australian media presence; risk of over-communication; cautious about high-profile advocacy before data. - **Clinical data uncertainty**: ICS longitudinal data still being analyzed; primary focus on peak immune response during dosing. ### Key quotes > “what we're looking at with the data right now is patients at baseline prior to their treatment and then looking at them during the course of CVac treatment and looking at how their immune profiles respond.” > “I think it's probably just a simple of an answer as, you know, we've been increasing our time here in the US, introducing the company to the investor community.” — Matthew Lehman > “we hold significant positions in euro and in US dollars, which is giving us a nice buffer in terms of the decrease of the Australian dollar which we have been seeing.” — Marc Voigt > “we certainly take the opportunity both on the financial community as well as the media to take some opportunities to be able to explain our story – tell our story in the media.” > “depending on the country, we may see anything from a half to about a patient per clinical center per month, depending on what we're -- where we're looking and how many patients their referral areas are.” ## Quarter one-liners - **2013 Q4:** Prima Biomed discusses CANVAS trial recruitment strategy, ICS immune monitoring data, FX hedging, and US investor outreach in Q4 2013 call. - **2013 Q1:** IMMP discusses Saxony grant, Phase 2 trial design, manufacturing progress, SPP for cash runway, and catalysts including CAN-003 results in H2 2013. ## Theme arcs - **Financing risk** (resolved): Cash‑runway and SPP concerns highlighted in Q1 but not mentioned in Q4 - **Clinical development design risk** (resolved): Phase‑2 indication selection discussed in Q1, absent in Q4 - **Manufacturing risk** (resolved): Manufacturing scale‑up and supplier reliance noted in Q1, not revisited in Q4 - **Competitive risk** (resolved): Early‑stage 2‑step immunotherapy competition mentioned in Q1 only - **Market risk (share price)** (resolved): Low share price limiting equity options discussed in Q1, not in Q4 - **Clinical trial recruitment risk** (new): Recruitment variability for CANVAS trial highlighted in Q4 - **Foreign exchange risk** (new): AUD/EUR exposure and hedging strategy introduced in Q4 - **US investor outreach** (new): Active outreach to US investors noted in Q4 - **Media/communication risk** (new): Australian media presence at risk and cautious communication discussed in Q4 ## Fear persistence - **Financing risk** [resolved]: Cash‑runway concerns raised in Q1, not present in Q4 - **Clinical development design risk** [resolved]: Indication selection risk discussed in Q1, absent in Q4 - **Manufacturing risk** [resolved]: Manufacturing qualification risk highlighted in Q1, not repeated in Q4 - **Competitive risk** [resolved]: Early‑stage competition risk noted in Q1 only - **Market risk (share price)** [resolved]: Low share price limiting equity options mentioned in Q1, not in Q4 - **Clinical trial recruitment risk** [new]: Recruitment variability for CANVAS trial introduced in Q4 - **Foreign exchange risk** [new]: Currency exposure and hedging discussed in Q4 - **Media/communication risk** [new]: Australian media presence at risk highlighted in Q4 - **Clinical data uncertainty** [new]: ICS longitudinal data still being analyzed, noted in Q4 ## Guidance path 2013 Q1:vague → 2013 Q4:vague --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/IMMP`